Lilly Opens Infusion Centers for High-Risk Hoosiers
(photo courtesy: Eli Lilly & Co.)
Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowIndianapolis-based Eli Lilly and Co. (NYSE: LLY) is partnering with local health systems to launch dedicated infusion centers throughout the state. The centers are designed to provide residents with access to COVID-19 treatments such as Lilly’s FDA-authorized antibody therapies.
Lilly is partnering with Ascension St. Vincent, Community Health Network, Eskenazi Health, Franciscan Health, Saint Joseph Health System, Beacon Health System and Goshen Health System on the infusion centers.
To date, Lilly says the centers have delivered antibody treatments to more than 1,700 Hoosiers at high-risk of contracting COVID-19.
“Throughout the implementation of our COVID-19 antibody clinical development program, we have identified multiple approaches to address many of the challenges this virus has presented, including complexities experienced with intravenous administration during the pandemic,” said Rob Metcalf, senior vice president of clinical development at Lilly. “We are pleased to share our insights with the goal of enabling health systems to quickly provide access to the COVID-19 antibody therapies needed to fight this devastating virus in high-risk symptomatic patients.”
The infusion centers are located at:
- Northern Indiana: COVID Infusion Center 60205 Bodnar Blvd. Mishawaka, IN 46544
- Central Indiana: Neurodiagnostic Center 5435 East 16th Street, 4th floor, Indianapolis, IN 46218
- Southern Indiana: Ascension St. Vincent Evansville 100 St Mary’s Epworth Crossing, Evansville, IN 47630
Lilly says it is sharing insights gathered from the infusion centers with governments, health systems and other stakeholders to help other locations open to serve more patients.
